JPS6365050B2 - - Google Patents
Info
- Publication number
- JPS6365050B2 JPS6365050B2 JP57180547A JP18054782A JPS6365050B2 JP S6365050 B2 JPS6365050 B2 JP S6365050B2 JP 57180547 A JP57180547 A JP 57180547A JP 18054782 A JP18054782 A JP 18054782A JP S6365050 B2 JPS6365050 B2 JP S6365050B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antiviral
- interferon
- surfactant
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000014150 Interferons Human genes 0.000 claims description 66
- 108010050904 Interferons Proteins 0.000 claims description 66
- 229940079322 interferon Drugs 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 52
- 239000004094 surface-active agent Substances 0.000 claims description 45
- 230000000840 anti-viral effect Effects 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 41
- 239000002736 nonionic surfactant Substances 0.000 claims description 33
- 208000009889 Herpes Simplex Diseases 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 241000282412 Homo Species 0.000 claims description 10
- 102000006992 Interferon-alpha Human genes 0.000 claims description 8
- 108010047761 Interferon-alpha Proteins 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002480 mineral oil Substances 0.000 claims description 7
- 235000010446 mineral oil Nutrition 0.000 claims description 7
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical group CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 3
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
- 238000000034 method Methods 0.000 description 37
- 239000008194 pharmaceutical composition Substances 0.000 description 37
- 241000700605 Viruses Species 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 27
- 241000700584 Simplexvirus Species 0.000 description 20
- 208000017520 skin disease Diseases 0.000 description 20
- 230000003211 malignant effect Effects 0.000 description 17
- 201000004681 Psoriasis Diseases 0.000 description 14
- 208000007514 Herpes zoster Diseases 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 11
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940047124 interferons Drugs 0.000 description 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 7
- 208000002741 leukoplakia Diseases 0.000 description 7
- 125000000129 anionic group Chemical group 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- -1 uracil pentafluoride Chemical compound 0.000 description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 208000001688 Herpes Genitalis Diseases 0.000 description 4
- 208000004898 Herpes Labialis Diseases 0.000 description 4
- 206010067152 Oral herpes Diseases 0.000 description 4
- 208000037048 Prodromal Symptoms Diseases 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000003093 cationic surfactant Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 201000004946 genital herpes Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000008058 pain sensation Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010000496 acne Diseases 0.000 description 3
- 208000009621 actinic keratosis Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003433 contraceptive agent Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- XLBLMKKJYRLJNT-UHFFFAOYSA-N 1H-pyrimidine-2,4-dione hydrofluoride Chemical compound O=C(C=CN1)NC1=O.F XLBLMKKJYRLJNT-UHFFFAOYSA-N 0.000 description 2
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940124558 contraceptive agent Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000003581 cosmetic carrier Substances 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229940087419 nonoxynol-9 Drugs 0.000 description 2
- 229920004918 nonoxynol-9 Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008250 pharmaceutical cream Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008132 rose water Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31103581A | 1981-10-13 | 1981-10-13 | |
| US311035 | 1981-10-13 | ||
| US388260 | 2003-03-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5877824A JPS5877824A (ja) | 1983-05-11 |
| JPS6365050B2 true JPS6365050B2 (it) | 1988-12-14 |
Family
ID=23205109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57180547A Granted JPS5877824A (ja) | 1981-10-13 | 1982-10-13 | インターフェロンを含む組成物 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5877824A (it) |
| CA (1) | CA1190148A (it) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0285443U (it) * | 1988-12-22 | 1990-07-04 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080032A3 (en) * | 1981-11-20 | 1985-11-13 | Enzo Biochem, Inc. | Pharmaceutical preparation for treating herpetic lesions |
| DE3436638C2 (de) * | 1984-10-05 | 1992-10-08 | Bioferon biochemische Substanzen GmbH & Co, 7958 Laupheim | Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur Behandlung rheumatischer Erkrankungen |
| JPS61277633A (ja) * | 1985-05-31 | 1986-12-08 | Toray Ind Inc | インタ−フエロン組成物 |
| JPS62185030A (ja) * | 1986-02-07 | 1987-08-13 | Toray Ind Inc | 経鼻投与用インタ−フエロン製剤 |
| CA1294215C (en) * | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
| CA1321347C (en) * | 1986-11-10 | 1993-08-17 | David C. Munch | Human leukocyte interferon composition and skin treatment |
| DE3731255A1 (de) * | 1987-09-17 | 1989-04-06 | Boehringer Ingelheim Int | Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen |
| AP132A (en) * | 1990-02-01 | 1991-05-19 | Kenya Medical Res Institute | Improved formulation of low-dose interferon alpha. |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
| JPS5283936A (en) * | 1976-01-01 | 1977-07-13 | Ortho Pharma Corp | Single herpes virus inactivating acent |
| US4184917A (en) * | 1974-04-01 | 1980-01-22 | Sandoz Ltd. | Process for producing a structurally modified interferon |
| JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
| JPS5594320A (en) * | 1978-11-24 | 1980-07-17 | Hoffmann La Roche | Interferon |
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
| JPS5622794A (en) * | 1979-07-31 | 1981-03-03 | Hoffmann La Roche | Human fibroblast interferon |
-
1982
- 1982-10-12 CA CA000413238A patent/CA1190148A/en not_active Expired
- 1982-10-13 JP JP57180547A patent/JPS5877824A/ja active Granted
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4184917A (en) * | 1974-04-01 | 1980-01-22 | Sandoz Ltd. | Process for producing a structurally modified interferon |
| US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
| US4139630A (en) * | 1974-12-03 | 1979-02-13 | Ortho Pharmaceutical Corp. | Nonionic surface active anti-viral agents |
| JPS5283936A (en) * | 1976-01-01 | 1977-07-13 | Ortho Pharma Corp | Single herpes virus inactivating acent |
| JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
| JPS5594320A (en) * | 1978-11-24 | 1980-07-17 | Hoffmann La Roche | Interferon |
| JPS55102519A (en) * | 1979-01-31 | 1980-08-05 | Green Cross Corp:The | Stabilization of interferon |
| JPS5622794A (en) * | 1979-07-31 | 1981-03-03 | Hoffmann La Roche | Human fibroblast interferon |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0285443U (it) * | 1988-12-22 | 1990-07-04 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1190148A (en) | 1985-07-09 |
| JPS5877824A (ja) | 1983-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4507281A (en) | Interferon-containing compositions | |
| EP0077063B1 (en) | Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis | |
| US4309989A (en) | Topical application of medication by ultrasound with coupling agent | |
| CA1083040A (en) | Topical application of medication by ultrasound with coupling agent | |
| AU746756B2 (en) | A method of inhibiting formation of infectious herpes virus particles | |
| CA1297006C (en) | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like | |
| GB2078515A (en) | Topical anti-viral preparation | |
| MXPA00009705A (es) | Uso de poliaminas en el tratamiento de sintomas dermatologicos. | |
| JPH0739347B2 (ja) | 硫酸化糖類の用途 | |
| EP0869789A1 (en) | Antiviral agent | |
| EP1094807B1 (en) | Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies | |
| US4957734A (en) | Treatment of certain skin malignancies and pre-malignant skin lesions, herpes zoster and psoriasis | |
| US4708873A (en) | Method of chemically debriding uncerated necrotic tissue | |
| JPS6365050B2 (it) | ||
| US4049798A (en) | Method for the treatment of Herpes Simplex | |
| JP3180221B2 (ja) | ヘルペス・シンプレックス・ウィルス感染治療用医薬組成物 | |
| JPS58103324A (ja) | インタ−フエロン組成物及びヘルペス感染症の治療における該組成物の使用 | |
| US5106879A (en) | Treatment for inflammatory skin disease | |
| US5977176A (en) | Compositions for the treatment of warts and herpes | |
| Nelson et al. | Clinical aspects of cutaneous leishmaniasis acquired in Texas | |
| JPH03500656A (ja) | ウイルス感染の治療および予防薬剤アシル・カルニチン | |
| EP0078533B1 (en) | Medicinal composition for treating skin disorders | |
| US8492443B2 (en) | Treatment for herpes simplex virus and other infectious diseases | |
| CA1227754A (en) | Use of tolnaftate in the treatment of herpes labialis | |
| CA1260397B (en) | Treatment of acne and perioral dermatitis as well as for skin infected with a herpesvirus |